| P2093 | author name string | Alexander R Cobitz | |
| | Steven Zeig | |
| | Gitanjali Paul | |
| | Borut Cizman | |
| | Andy P Sykes | |
| P2860 | cites work | Current and future chemical therapies for treating anaemia in chronic kidney disease | Q38690858 |
| | Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. | Q41823201 |
| | Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation | Q43258997 |
| | Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure | Q44948985 |
| | Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study | Q46141374 |
| | A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial | Q48068592 |
| | A method to determine the optimal intensity of oral anticoagulant therapy. | Q51058560 |
| | A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. | Q53193067 |
| | Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. | Q53630003 |
| | Candidate biomarkers for erythropoietin response in end-stage renal disease. | Q54282807 |
| | Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. | Q55059867 |
| | Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial | Q33356816 |
| | Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics | Q34593321 |
| | Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients | Q35748297 |
| | Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients | Q36736661 |
| | Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia | Q36746039 |
| | Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients | Q36746098 |
| | Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies | Q36988477 |
| | Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study | Q37257340 |
| | Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management | Q37611388 |
| P433 | issue | 4 | |
| P921 | main subject | erythropoietin | Q218706 |
| P304 | page(s) | 841-850 | |
| P577 | publication date | 2018-03-03 | |
| P1433 | published in | KI reports | Q27727507 |
| P1476 | title | An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects | |
| P478 | volume | 3 | |